Diaceutics and London Genetics to Develop Software for Biomarker Studies
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Diaceutics, a developer of a series of decision tools to help with the issues arising from personalized medicine and theranostics, and London Genetics, a company that uses pharmacogenetics in clinical drug discovery and development, have announced a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups.
The new tools will enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences, as well as the researchers and clinicians relevant to their targeted therapy research.
The new software, which is expected to be launched in 2011, is based on the Diaceutics Fusion platform, a personalized medicine planning software application for targeted therapy development teams, and the London Genetics Biomarker Pathway platform. The tools to be developed under the strategic partnership will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development.
The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics's own network of over 3,000 investigators in a broad range of therapeutic areas and technology disciplines. In this way, partners can be rapidly identified and collaborative projects instigated, reported Diaceutics.
Dominique Kleyn, CEO of London Genetics, said: "This strategic alliance with Diaceutics fits closely with our overall goal to expedite pharmacogenetic and biomarker partnerships between industry and academia for more effective targeted drug development. We look forward to working with new industry partners identified via the tools we are developing with Diaceutics."
The new tools will enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences, as well as the researchers and clinicians relevant to their targeted therapy research.
The new software, which is expected to be launched in 2011, is based on the Diaceutics Fusion platform, a personalized medicine planning software application for targeted therapy development teams, and the London Genetics Biomarker Pathway platform. The tools to be developed under the strategic partnership will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development.
The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics's own network of over 3,000 investigators in a broad range of therapeutic areas and technology disciplines. In this way, partners can be rapidly identified and collaborative projects instigated, reported Diaceutics.
Dominique Kleyn, CEO of London Genetics, said: "This strategic alliance with Diaceutics fits closely with our overall goal to expedite pharmacogenetic and biomarker partnerships between industry and academia for more effective targeted drug development. We look forward to working with new industry partners identified via the tools we are developing with Diaceutics."
